Ocrelizumab Trial Fills Research Gap for Black, Hispanic MS Patients

MedPage Today) — DENVER — Among Black/African American and Hispanic/Latino patients with relapsing multiple sclerosis (MS) in the phase IV CHIMES trial, half achieved a combined measure for no evidence of disease activity (NEDA) with ocrelizumab…
Read More

About The Author

Jonathan Jeriah

See author's posts